Tema ETFs LLC Buys 1,743 Shares of Stryker Corporation $SYK

Tema ETFs LLC raised its stake in Stryker Corporation (NYSE:SYK) by 31.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 7,306 shares of the medical technology company’s stock after acquiring an additional 1,743 shares during the quarter. Tema ETFs LLC’s holdings in Stryker were worth $2,300,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC increased its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares during the last quarter. Schnieders Capital Management LLC. purchased a new position in shares of Stryker during the 2nd quarter valued at $205,000. Marshall Wace LLP lifted its position in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after buying an additional 77,831 shares during the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the 2nd quarter worth $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker in the 2nd quarter worth about $253,000. 77.09% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Stryker news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $347.15 on Thursday. The business’s fifty day moving average is $323.14 and its 200 day moving average is $333.62. The firm has a market cap of $133.16 billion, a price-to-earnings ratio of 35.97, a PEG ratio of 2.22 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $396.86.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm’s revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts predict that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.0%. Stryker’s payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on SYK shares. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Needham & Company LLC cut their target price on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Robert W. Baird set a $385.00 target price on shares of Stryker in a research note on Friday, May 1st. Raymond James Financial set a $370.00 price target on shares of Stryker in a research report on Friday, July 31st. Finally, UBS Group assumed coverage on shares of Stryker in a research note on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.